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1  |  INTRODUC TION
Breast	cancer	is	the	most	common	cancer	recorded	in	Australian	




cancer survival, attributed mostly to treatment advances and ear-
lier	 detection	 from	 population	 screening	 (Australia	 Government	
and	Department	 of	 Health,	 2014;	 Australian	 Institute	 of	 Health	
and	Welfare,	2019;).
Australian	 and	 international	 studies	 show	 females	 with	




Breast	cancer	 treatment	has	changed	 in	 recent	decades	 in	 line	
with better understanding of disease biology, pharmacological dis-
coveries	and	advances	in	clinical	practice	(Hortobagyi,	2020;	Waks	
&	Winer,	 2019).	 Treatment	 generally	 includes	 surgery,	 and,	where	
appropriate,	 adjuvant	 radiotherapy	 and	 systemic	 therapy	 (Cancer	
Australia,	2000,	2001).	Breast-	conserving	surgery	is	now	more	com-
mon than mastectomy, and systemic therapies have broadened be-
yond chemotherapy to include hormone and targeted therapies and 
immunotherapy	(Cancer	Australia,	2000,	2001).
Apart	from	clinical	factors,	such	as	cancer	stage,	histology,	dif-
ferentiation, hormone receptor status and general health status, 
treatment and outcomes can vary with age at diagnosis, cultural 
background,	 socioeconomic	 status	 and	 residential	 remoteness.	
Breast	 cancer	 treatment	 and	 survival	 have	 been	 investigated	 in	
South	 Australia	 using	 registry	 data	 from	 several	 public	 hospitals	
(Roder	et	 al.,	 2017),	 but	 corresponding	population-	wide	 investiga-
tions have not been possible with registry data alone due to gaps in 
treatment data.
Health	services	seek	data	to	assess	trends	in	treatment	and	sur-





The	 present	 study	 investigates	 population-	wide	 differences	
and	trends	in	breast	cancer	care	and	outcomes	using	linked	cancer	
registry, hospital inpatient, radiotherapy and universal medical and 
pharmaceutical health insurance data for breast cancers diagnosed 
in	South	Australia	in	2000–	2014.
2  |  METHODS
2.1  |  Data sources and linkage
Invasive	female	breast	cancer	data	(ICD-	O-	3,	C50)	from	the	South	
Australian	 Cancer	 Registry	 (SACR)	 comprised	 the	 main	 linkage	
spine.	SACR	uses	international	registry	standards	with	legally	man-
dated	reporting	from	pathology	laboratories	and	hospitals	(Esteban	
et	 al.,	 1995;	 South	 Australian	 Cancer	 Registry:	 Epidemiology	
Branch,	 2000).	 The	 SACR	 is	 population-	based,	 recording	 primary	
cancer site, histology, diagnosis date, and person's age, coun-
try	 of	 birth,	 postcode-	derived	 relative	 socioeconomic	 disadvan-
tage and geographic remoteness, plus radiotherapy notifications 
(South	 Australian	 Cancer	 Registry:	 Epidemiology	 Branch,	 2000).	
The	 Registry	 of	 Births,	 Deaths	 and	Marriages	 and	 Australia-	wide	
National Death Index is used to obtain death dates and causes, clas-
sified	 by	 cancer	 type	 or	 as	 non-	cancer	 (South	 Australian	 Cancer	
Registry:	Epidemiology	Branch,	2000).
Treatment data mostly were extracted from hospital inpatient 
databases, radiotherapy centres and universal health insurance 
claims	 (i.e.	claims	under	 the	Medical	Benefits	Schedule	 [MBS]	and	
Pharmaceutical	Benefits	Scheme	[PBS]).	Hospital	inpatient	data	in-
cluded dates of admission and clinical procedure codes, whereas ra-
diotherapy centre data included dates of all treatments.
Collectively, data from these sources covered most treatment. 
MBS	 and	 PBS	 subsidise	 privately	 funded	 hospital	 and	 community	
treatments	and	costs	of	drugs	(Australian	Government,	Department	
of	Health,	2020a,	2020b).
Linkage	 of	 SACR	 and	 hospital	 data	 was	 undertaken	 by	 SANT	
Data	 Link,	 with	 97%	 deterministic	 matching	 to	 a	 Master	 linkage	
file derived from 60 data sources, and with subsequent probabilis-
tic	matching	(using	name,	sex,	date	of	birth	and	address)	and	cleri-
cal	 review	of	uncertain	matches	 (Australian	Government,	National	
Statistical	 Service,	 2017).	 This	 followed	 the	 principle	 of	 separat-
ing patient identifiers from clinical content data to protect privacy 




2.2  |  Cancer treatment
Treatment in the first 12 months from diagnosis was investi-
gated according to whether any was recorded, that is any surgery 
lower	survival	and	less	treatment.	More	trial	evidence	is	needed	to	optimise	trade-	
offs between benefits and harms in these older women. Survival differences were 
not found by residential remoteness and were marginal by socioeconomic status.
K E Y W O R D S
breast	cancer,	differences,	South	Australia,	survival,	treatment
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(mastectomy,	 breast-	conserving	 surgery	 or	 both),	 radiotherapy	
or systemic therapy. Systemic therapies comprised chemother-
apy, hormonal drugs, targeted and immunotherapies. Data for a 
subset	 of	 systemic	 therapies	 reimbursed	 through	 the	 PBS	 were	
also available to identify hormonal treatments. Data sources 
included: for surgery— inpatient databases; for radiotherapy— 
inpatient	+radiotherapy	+	SACR	+	MBS;	and	for	systemic	therapy—	
inpatient	+	PBS	+	MBS.	Codes	used	for	treatment	types	were	those	
included	 in	 the	 10th	 Revision	 of	 the	 Australian	 Classification	 of	
Health	Interventions	and	MBS	and	PBS	coding	systems	(Australian	
Government, Department of Health, 2020a, 2020b; National Centre 
for	Classification	in	Health,	2010).
2.3  |  Other descriptors
Age	 at	 diagnosis	 was	 classified	 as:	 <50,	 50–	59,	 60–	69,	 70–	79	 or	
80+	years.	To	compare	outcomes	by	cultural	background,	country	
of	birth	was	classified	as	Australia,	other	mainly	English-	speaking	or	
non-	English-	speaking	 country,	 as	 described	 previously	 (Australian	
Bureau	of	Statistics,	2008).	Socioeconomic	status	was	derived	from	
residential postcode at diagnosis using the Socioeconomic Index for 
Areas	Index	of	Relative	Socio-	economic	Disadvantage	expressed	in	
quintiles	(Australian	Bureau	of	Statistics,	2019).	Residential	area	was	
classified as a major city area, inner regional, outer regional, remote 
or	 very	 remote	 area,	 using	 the	 Australian	 Standard	 Geographical	
Classification	 Remoteness	 index	 (Australian	 Bureau	 of	 Statistics,	
2006).
Cancer descriptors included stage, histology, differentiation, and 
for subsets, oestrogen receptor status and human epidermal growth 
factor	receptor	2	(HER2)	status.	Stage	was	derived	from	pathology	
laboratory, hospital and clinical reporting and broadly classified for 
study	purposes	 as	TNM	stage	 I,	 II,	 III	 or	 IV	 (Walters	 et	 al.,	 2013).	
Cancer differentiation was categorised as low, intermediate or high, 
histology	as	ductal,	lobular	or	other	(not	ductal	or	lobular),	and	oes-




ment side effects arising during or soon after treatment, that is dia-
betes mellitus ± complications, dementia, pulmonary diseases, acute 
myocardial infarction, congestive heart failure, connective tissue 
diseases, peptic ulcer, liver diseases, paraplegia, renal diseases, other 
cancers,	severe	liver	disease	and	HIV	(Quan	et	al.,	2005).
2.4  |  Statistical analysis
Breast	 cancer	 treatment	was	 compared	 by	 sociodemographic	 and	
cancer	 characteristic	 using	 the	 conventional	 chi-	square	 or	 non-	
parametric	ranked	test	depending	on	variable	distribution.	Logistic	
regression was used to model treatment after adjusting for dif-
ferences	 in	 sociodemographic	 variables,	 year	 of	 diagnosis,	 TNM	
stage,	 differentiation,	 histology	 and	 comorbidity	 status	 (Stata	 14;	
StataCorp).
Deaths were coded as due to breast cancer, another cancer or 
another cause, and predictors of survival from breast cancer were 




Predictors of breast cancer death were investigated using multi-
variate	competing	risk	regression	(Stata	module	‘stcrreg’),	adjusting	
for	sociodemographic	characteristics,	TNM	stage,	cancer	histology,	





statistical significance level set as p	<	0.05.	Analyses	were	based	on	
complete case data. Diagnostic period was treated as an adjustment 
variable rather than a primary variable for radiotherapy and systemic 
therapy, due to changes in funding arrangements which altered 
methods of data collection.
3  |  RESULTS
3.1  |  Patient profile
Overall,	 21%	of	patients	were	aged	<50	years	 and	10%	were	80+	




3.2  |  Cancer profile







3.3  |  Breast cancer treatment
3.3.1  |  Any	treatment
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TA B L E  1 Patient	and	clinical	factors	for	breast	cancers	with	treatment	within	12	months	following	diagnosisa	during	2000–	2014	
(N	=	13,494).
No treatment (n = 210)
Having treatment 




<50	(n	=	2819) 10	(4.8%) 2809	(21.2%) 1.00
50–	59	(n	=	3466) 14	(6.7%) 3452	(26.0%) 0.89	(0.39–	2.03)
60–	69	(n	=	3584) 26	(12.4%) 3558	(26.8%) 0.55	(0.26–	1.16)
70–	79	(n	=	2244) 58	(27.6%) 2186	(16.5%) 0.18	(0.09–	0.36)
80+	(n	=	1381) 102	(48.6%) 1279	(9.6%) 0.10	(0.05–	0.20)
Country of birth 0.004







Unknown	(n	=	241) 14 227 0.48	(0.25–	0.94)
SEIFA	quintile 0.315
Most	disadvantage	(n	=	2322) 38	(18.1%) 2284	(17.2%) 1.00
2	(n	=	2661) 46	(21.9%) 2615	(19.7%) 0.75	(0.47–	1.21)
3	(n	=	2735) 50	(23.8%) 2685	(20.2%) 0.70	(0.47–	1.21)
4	(n	=	2680) 39	(18.6%) 2641	(19.9%) 0.87	(0.52–	1.43)
Least	disadvantage	(n	=	3095) 37	(17.6%) 3058	(23.0%) 1.20	(0.72–	2.00)
Remoteness 0.068
Major	city	(n	=	9985) 170	(81.0%) 9815	(73.9%) 1.00
Inner	regional	(n	=	1529) 17	(8.1%) 1512	(11.4%) 1.42	(0.83–	2.43)
Outer	and	remote	(n	=	1980) 23	(11.0%) 1957	(14.7%) 1.46	(0.88–	2.42)
Histology 0.298
Ductal	(n	=	10,454) 129	(77.7%) 10,325	(79.0%) 1.00
Lobular	(n	=	1387) 14	(8.4%) 1373	(10.5%) 1.41	(0.78–	2.55)
Other	(n	=	1399) 23	(13.9%) 1376	(10.5%) 1.24	(0.75–	2.03)
Unknown	(n	=	254) 44 210 0.62	(0.39–	1.01)
Differentiation 0.679
Low	(n	=	4127) 34	(31.8%) 4093	(32.6%) 1.00
Intermediate	(n	=	5689) 52	(48.6%) 5637	(44.8%) 0.92 
(0.59–	–	1.44)
High	(n	=	2865) 21	(19.6%) 2844	(22.6%) 1.01	(0.57–	1.80)
Unknown	(n	=	813) 103 710 0.21	(0.13–	0.34)
TNM	staging <0.001
I	(n	=	5462) 32	(23.5%) 5430	(45.4%) 1.00
II	(n	=	4799) 43	(31.6%) 4756	(39.7%) 0.68	(0.42–	1.09)
III	(n	=	1389) 5	(3.7%) 1384	(11.6%) 1.88	(0.72–	4.93)
IV	(n	=	458) 56	(41.2%) 402	(3.4%) 0.13	(0.08–	0.22)
Unknown	(n	=	1386) 74 1312 0.24	(0.15–	0.38)
Charlson Index <0.001
0	(n	=	12,535) 169	(80.5%) 12,366	(93.1%) 1.00
1–	2	(n	=	907) 32	(15.2%) 875	(6.6%) 0.90	(0.58–	1.39)
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0.10,	95%	CI	0.05–	0.20	 for	80+	years).	 Patients	born	 in	 another	
mainly	English-	speaking	country	had	lower	odds	of	any	treatment	
than	 the	 Australian-	born	 (aOR	 0.63,	 95%	 CI	 0.43–	0.92).	 Those	
with	stage	IV	cancers	had	lower	odds	than	for	stage	I	to	have	any	
treatment	(aOR	0.13,	95%	CI	0.08–	0.22).	No	difference	was	found	
in treatment status by socioeconomic disadvantage, remoteness, 
histology type, differentiation, diagnostic period or comorbidity 
status	(Table	1).
3.3.2  |  Surgical	treatment

























and	0.51,	 95%	CI	0.37–	0.70	 respectively),	 but	more	 likely	 to	 have	
mastectomy	 (aOR	1.35,	95%	CI	1.09–	1.67	and	1.70	95%	CI	1.30–	
2.23	respectively).





Almost	 three-	quarters	 of	 women	 (72%,	 9691)	 had	 systemic	
therapy	(Table	3;	Table	S2).	The	odds	ratio	for	systemic	therapy:	
reduced	with	age	from	<50	years	to	an	aOR	0.37	(95%	CI	0.32–	
0.43)	 for	80+	years;	was	higher	 at	1.24	 (95%	CI	1.10–	1.40)	 for	
patients	 born	 in	 other	 mainly	 non-	English-	speaking	 countries	
compared	with	the	Australian-	born;	was	lowest	in	residents	from	
the most disadvantaged area; and by comparison, was highest at 
1.43	(95%	CI	1.26–	1.63)	in	those	from	least	disadvantaged	areas	
(Table	3).
The adjusted odds ratio for systemic therapy was not different 
by	histology	or	presence	of	 comorbidity,	 but	was	higher	 for	TNM	
stages	>stage	I	and	lower	for	higher	differentiation	(Table	3).
3.3.4  |  Radiotherapy




years	 (Table	 3).	 Patients	 born	 in	 mainly	 non-	English-	speaking	
countries had an elevated odd ratio for radiotherapy at aOR 1.13 
(95%	CI	1.01–	1.26)	compared	with	the	Australian-	born.	A	lower	
aOR	 0.88	 (95%	CI	 0.78–	0.99)	 for	 radiotherapy	 applied	 to	 resi-
dents of outer regional and remote areas compared with major 
city areas.
Differences in use of radiotherapy presented by differentiation 
and	TNM	stage	but	did	not	show	a	consistent	pattern	(Table	3;	Table	
S3).	Associations	with	radiotherapy	use	were	not	seen	by	socioeco-
nomic disadvantage of residential area, tumour histology or comor-
bidity status.
A	 difference	 presented	 by	 surgery	 type	where	women	 having	
breast-	conserving	 surgery	 were	 more	 likely	 than	 those	 having	 a	
mastectomy	to	receive	radiotherapy	at	aOR	5.68	(95%	CI	5.11–	6.30).	
This	difference	applied	to	stage	I	at	OR	14.49	(95%	CI	11.80–	17.80),	




For	 the	 subset	 of	 cases	 of	 known	 hormone	 treatment	 status,	 use	
of	hormone	agents	applied	to	85%	(92%	when	oestrogen	receptor	
status	was	positive).	Use	of	hormone	therapy	was	higher	in	women	
aged	70+	 years	 (Table	 3;	 Table	 S4).	 Compared	with	 patients	 aged	
<50	years,	 the	odds	 ratio	 for	hormone	use	was	aOR	1.58	 (95%	CI	
1.15–	2.16)	for	ages	70–	79	years	and	aOR	1.55	(95%	CI	1.07–	2.25)	for	
ages	80+	years.	A	greater	use	of	these	treatments	was	also	evident	







ent by level of residential area disadvantage or remoteness or pres-
ence	of	comorbidity	(Table	3).
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TA B L E  2 Adjusted	odds	ratiosa	(95%	CIs)	for	having	surgery	within	12	months	following	breast	cancer	diagnosisb	(n	=	12,204).
Conservative (n = 7498) Mastectomy (n = 3491)
Conservative and 
mastectomy (n = 1215)
Age	at	diagnosis	(years)
<50	(n	=	2819) 1.00
50–	59	(n	=	3466) 1.48	(1.17–	1.86) 1.14	(0.91–	1.45) 0.86	(0.66–	1.12)
60–	69	(n	=	3584) 1.56	(1.24–	1.97) 1.11	(0.87–	1.41) 0.68	(0.52–	0.90)
70–	79	(n	=	2244) 1.20	(0.94–	1.53) 1.11	(0.86–	1.43) 0.53	(0.39–	0.72)
80+	(n	=	1381) 0.45	(0.36–	0.58) 0.35	(0.28–	0.46) 0.14	(0.10–	0.20)
Country of birth
Australia	(n	=	9281) 1.00
Other	mainly	English-	speaking	countries	(n	=	2235) 1.05	(0.85–	1.29) 1.08	(0.86–	1.33) 1.07	(0.84–	1.38)
Mainly	non-	English-	speaking	countries	(n	=	1737) 1.10	(0.88–	1.39) 1.19	(0.94–	1.51) 1.11	(0.84–	1.47)
Unknown	(n	=	241) 0.22	(0.15–	0.32) 0.20	(0.13–	0.32) 0.13	(0.06–	0.26)
SEIFA	quintile
1	most	disadvantage	(n	=	2322) 1.00
2	(n	=	2661) 1.12	(0.88–	1.43) 0.99	(0.77–	1.27) 0.92	(0.69–	1.23)
3	(n	=	2735) 1.07	(0.84–	1.36) 0.99	(0.77–	1.27) 0.87	(0.65–	1.16)
4	(n	=	2680) 0.95	(0.74–	1.21) 0.77	(0.59–	0.99) 0.70	(0.52–	0.94)
5	least	disadvantage	(n	=	3095) 0.99	(0.77–	1.26) 0.88	(0.68–	1.13) 0.73	(0.54–	0.98)
Remoteness
Major	city	(n	=	9985) 1.00
Inner	regional	(n	=	1529) 1.22	(0.95–	1.56) 1.12	(0.86–	1.45) 1.18	(0.88–	1.59)
Outer	and	remote	(n	=	1980) 0.87	(0.69–	1.08) 1.03	(0.82–	1.30) 0.91	(0.69–	1.19)
Diagnosis year
2000–	2004	(n	=	4047) 1.00
2005–	2009	(n	=	4410) 1.07	(0.88–	1.28) 1.34	(1.10–	1.63) 1.20	(0.95–	1.50)
2010–	2014	(n	=	5037) 1.27	(1.04–	1.53) 1.66	(1.36–	2.03) 1.40	(1.11–	1.76)
Histology
Ductal	(n	=	10,454) 1.00
Lobular	(n	=	1387) 0.85	(0.65–	1.09) 1.10	(0.85–	1.43) 1.09	(0.88–	1.36)
Other	(n	=	1399) 1.03	(0.80–	1.32) 0.80	(0.61–	1.04) 1.28	(0.95–	1.72)
Unknown	(n	=	254) 0.23	(0.15–	0.35) 0.18	(0.11–	0.31) 0.29	(0.20–	0.41)
Differentiation
Low	(n	=	4127) 1.00
Intermediate	(n	=	5689) 1.32	(1.10–	1.58) 1.03	(0.86–	1.25) 1.09	(0.88–	1.36)
High	(n	=	2865) 2.06	(1.60–	2.64) 1.00	(0.77–	1.31) 1.28	(0.95–	1.72)
Unknown	(n	=	813) 0.19	(0.15–	0.25) 0.19	(0.14–	0.25) 0.29	(0.20–	0.41)
TNM	staging
I	(n	=	5462) 1.00
II	(n	=	4799) 0.46	(0.38–	0.57) 1.35	(1.09–	1.67) 0.77	(0.61–	0.97)
III	(n	=	1389) 0.16	(0.12–	0.21) 1.70	(1.30–	2.23) 0.51	(0.37–	0.70)
IV	(n	=	458) 0.009	(0.006–	0.01) 0.05	(0.03–	0.07) 0.005	(0.002–	0.02)
Unknown	(n	=	1386) 0.16	(0.12–	0.19) 0.38	(0.29–	0.48) 0.24	(0.18–	0.32)
Charlson Index
0	(n	=	12,535) 1.00
1–	2	(n	=	907) 0.68	(0.52–	0.88) 0.81	(0.62–	1.06) 0.72	(0.51–	1.02)
3+	(n	=	52) 0.19	(0.07–	0.48) 0.26	(0.10–	0.67) 0.15	(0.02–	1.16)
Abbreviation:	SEIFA,	Socioeconomic	Index	for	Areas.
aAdjusted	odd	ratios	from	logistic	regression	analyses,	including	all	variables	in	the	Table.;	bNo surgery as reference, all cases diagnosed between 
2000–	2014.
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TA B L E  3 Adjusted	odds	ratiosa	(95%	CIs)	for	systemic	therapy,	radiotherapy	and	hormone	therapy	for	breast	cancer	within	12	months	
following	diagnosis	during	2000–	2014.
Systemic therapy (vs. no 
systemic treatment) n = 13,494
Radiotherapy (vs. no 
radiotherapy) n = 13,494
Hormone therapy (vs. no 
hormone therapy)b  n = 4262
Age	group
<50	(n	=	2819) 1.00
50–	59	(n	=	3466) 0.80	(0.70–	0.90) 1.08	(0.96–	1.20) 1.03	(0.82–	1.30)
60–	69	(n	=	3584) 0.52	(0.46–	0.59) 0.91	(0.82–	1.02) 1.19	(0.92–	1.52)
70–	79	(n	=	2244) 0.39	(0.34–	0.45) 0.40	(0.36–	0.45) 1.58	(1.15–	2.16)









Unknown	(n	=	241) 1.64	(1.18–	2.27) 1.21	(0.91–	1.62) 1.80	(0.63–	5.14)
SEIFA	quintile
1	most	disadvantage	(n	=	2322) 1.00
2	(n	=	2661) 1.24	(1.10–	1.41) 0.95	(0.84–	1.08) 0.93	(0.70–	1.23)
3	(n	=	2735) 1.15	(1.02–	1.31) 0.91	(0.81–	1.03) 1.04	(0.78–	1.39)
4	(n	=	2680) 1.26	(1.11–	1.44) 0.98	(0.88–	1.13) 1.14	(0.84–	1.54)
5	Least	disadvantage	(n	=	3095) 1.43	(1.26–	1.63) 0.92	(0.81–	1.04) 0.99	(0.74–	1.31)
Remoteness
Major	city	(n	=	9985) 1.00
Inner	regional	(n	=	1529) 0.98	(0.87–	1.11) 0.93	(0.82–	1.05) 1.09	(0.82–	1.46)
Outer	and	remote	(n	=	1980) 1.04	(0.92–	1.17) 0.88	(0.78–	0.99) 1.08	(0.82–	1.43)
Histology
Ductal	(n	=	10,454) 1.00
Lobular	(n	=	1387) 1.05	(0.93–	1.20) 1.00	(0.88–	1.13) 1.15	(0.82–	1.62)
Other	(n	=	1399) 0.96	(0.84–	1.08) 0.96	(0.85–	1.09) 0.92	(0.67–	1.25)
Unknown	(n	=	254) 0.98	(0.73–	1.32) 0.68	(0.50–	0.93) 3.04	(0.92–	10.05)
Differentiation
Low	(n	=	4127) 1.00
Intermediate	(n	=	5689) 0.70	(0.64–	0.78) 0.85	(0.77–	0.93) 2.70	(2.20–	3.30)
High	(n	=	2865) 0.59	(0.53–	0.67) 0.95	(0.85–	1.06) 3.64	(2.67–	4.94)
Unknown	(n	=	813) 0.62	(0.51–	0.74) 0.60	(0.50–	0.72) 2.25	(1.41–	3.62)
TNM	staging
I	(n	=	5462) 1.00
II	(n	=	4799) 1.52	(1.38–	1.66) 0.98	(0.90–	1.07) 0.92	(0.74–	1.14)
III	(n	=	1389) 1.89	(1.63–	2.20) 2.96	(2.54–	3.45) 0.61	(0.46–	0.80)
IV	(n	=	458) 1.75	(1.38–	2.22) 1.01	(0.81–	1.26) 0.86	(0.51–	1.46)
Unknown	(n	=	1386) 1.27	(1.11–	1.46) 0.67	(0.59–	0.77) 0.76	(0.55–	1.04)
Charlson Index
0	(n	=	12,535) 1.00
1–	2	(n	=	907) 0.92	(0.79–	1.07) 0.76	(0.66–	0.89) 0.87	(0.59–	1.29)
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3.4  |  Cancer survival





an elevated SHR applied to older age groups compared with women 
aged	<50	years	at	aSHR	1.54	(95%	CI	1.31–	1.82)	for	70–	79	years	and	
aSHR	2.04	(95%	CI	1.69–	2.47)	for	ages	80+	years.	Compared	with	





advantaged. Other differences included higher aSHRs for more ad-
vanced	TNM	stage	and	 in	 the	presence	of	 comorbidity,	 but	 lower	
aSHRs	for	higher	differentiation,	other	histology	 (i.e.	not	ductal	or	
lobular),	and	with	treatment	(Table	4).	Differences	in	aSHRs	were	not	
evident by country of birth or residential remoteness.
Surgery	was	a	key	predictor	of	survival.	Compared	with	no	sur-
gery,	aSHRs	were	0.31	(95%	CI	0.26–	0.36)	for	women	having	breast-	







which	 is	at	 the	high	end	of	 the	 international	scale	 (Allemani	et	al.,	
2018).	 We	 regard	 this	 as	 a	 positive	 finding	 despite	 uncertainties	
around potential influences from differences in registry practices, 
lead	time,	overdiagnosis	and	related	effects	(Allemani	et	al.,	2018).	
These	results	complement	the	age-	standardised	reduction	in	breast	
cancer	 mortality	 recorded	 at	 a	 population	 level	 for	 Australia	 be-
tween	1982	and	2019	 (Australian	 Institute	of	Health	and	Welfare,	
2019).
Survival was equivalent by residential remoteness and country 
of birth, which is reassuring from an equity perspective as it was 
anticipated	 that	 some	 women	 from	 mainly	 non-	English-	speaking	
countries may have lower survival due to language and cultural 
barriers.	Although	 the	difference	was	 small,	 residents	of	 the	 least	








with ageing, requirements for service adaptations at a population 
level to meet their needs will escalate. Increased attention to older 




decisions on clinical options for older people, and to develop better 
instruments for predicting the disease prognosis in the short term, 
such	 that	 complex	 trade-	off	 decisions	 can	 be	 facilitated	 (Li	 et	 al.,	
2018).
Surgical treatment was strongly associated with higher survival. 




Better	 measures	 of	 these	 characteristics	 are	 needed	 to	 quantify	
their effects at a population level.
Of	the	study	cohort,	98%	had	some	treatment	for	their	cancer,	
that is either surgery, radiotherapy, systemic or combination ther-
apy,	whereas	90%	had	surgery.	Treatment	by	surgery,	 irrespective	
of	 whether	 by	 breast-	conserving	 or	 mastectomy,	 increased	 over	
the	 study	 period.	 Approximately	 60%	 had	 breast-	conserving	 sur-
gery rather than a mastectomy, which accords with findings from 
other	Australian	studies	(Roder	et	al.,	2013;	South	Australian	Cancer	
Registry:	 Epidemiology	 Branch,	 2000).	 Breast-	conserving	 surgery	
rather	 than	mastectomy	was	more	 common	 at	 ages	 50–	69	 years,	
which	may	reflect	a	common	screening-	treatment	pathway	and	po-
tentially:	(1)	less	aggressive	cancers	than	in	younger	women;	and	(2)	
reluctance of less mobile older women to have radiotherapy, there-
fore opting for mastectomy.
Breast	surgery	was	less	common	for	women	aged	80+	years,	as	
previously	reported	(South	Australian	Cancer	Registry:	Epidemiology	
Branch,	 2000),	 probably	 due	 to	 increased	 frailty	 and	 comorbidity,	




to clear regional disease.
Irrespective	of	 surgery	 type,	 surgery	was	 least	 likely	 for	 stage	
IV	disease	where	the	potential	to	clear	the	disease	through	excision	
would generally have been lowest. Tumour differentiation was also 
predictive of surgery type with highly differentiated tumours more 
likely	than	poorly	differentiated	to	be	treated	by	breast-	conserving	
therapy.	Little	difference	in	exposure	to	surgery	was	evident	by	resi-
dential remoteness and socioeconomic status, which we interpret as 
positive in equity terms.
About	 70%	 of	 cohort	 members	 had	 systemic	 therapy	 in	 the	
12	months	 following	diagnosis.	A	 reducing	exposure	with	advanc-
ing	age	 is	consistent	with	previous	study	 results	 (South	Australian	
Cancer	 Registry:	 Epidemiology	 Branch,	 2000;	 Tesarova,	 2013),	
probably reflecting concerns whether patient resilience was enough 
to cope with treatment toxicity and also the potential, due to lower 
additional	 life	expectancy,	for	reduced	intermediate	and	long-	term	
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All	(n	=	13,494) 97.6 89.2 84.0
Age	at	diagnosis	(years)
<50	(n	=	2819) 98.9 90.7 85.5 <0.001 1.00
50–	59	(n	=	3466) 98.9 91.0 86.7 0.89	(0.76–	1.04) 1.06	(0.91–	1.24)
60–	69	(n	=	3584) 98.4 92.5 88.0 0.80	(0.69–	0.94) 1.06	(0.90–	1.24)
70–	79	(n	=	2244) 96.8 86.6 81.4 1.28	(1.09–	1.51) 1.54	(1.31–	1.82)
80+	(n	=	1381) 90.5 75.4 66.7 2.28	(1.94–	2.68) 2.04	(1.69–	2.47)
Country of birth
Australia	(n	=	9281) 97.8 89.2 84.1 0.156 1.00
Other	mainly	English-	speaking	
(n	=	2235)
97.2 89.3 84.1 1.02	(0.89–	1.17) 0.98	(0.84–	1.14)
Mainly	non-	English-	speaking	
(n	=	1737)
97.7 89.6 83.8 1.01	(0.87–	1.18) 0.92	(0.78–	1.08)
Unknown	(n	=	241) 90.7 82.9 78.9 1.46	(1.06–	2.00) 1.24	(0.87–	1.79)
Socioeconomic	(SEIFA)
Most	disadvantage	(n	=	2322) 97.2 87.1 80.7 <0.001 1.00
2	(n	=	2661) 97.5 88.4 83.0 0.89	(0.76–	1.04) 0.96	(0.81–	1.13)
3	(n	=	2735) 97.7 89.3 84.3 0.81	(0.70–	0.95) 0.87	(0.73–	1.02)
4	(n	=	2680) 97.6 89.4 84.0 0.84	(0.72–	0.98) 0.97	(0.82–	1.15)
Least	disadvantage	(n	=	3095) 97.9 91.0 87.0 0.68	(0.58–	0.80) 0.77	(0.65–	0.92)
Residential remoteness
Major	city	(n	=	9985) 97.5 89.4 84.3 0.799 1.00
Moderate	(n	=	1529) 98.1 88.4 83.9 1.02	(0.87–	1.20) 1.02	(0.87–	1.21)
High	(n	=	1980) 97.7 88.6 82.9 1.05	(0.91–	1.20) 0.96	(0.82–	1.12)
Cancer stage:
I	(n	=	5462) 99.8 97.7 95.7 <0.001 1.00
II	(n	=	4799) 99.3 90.4 84.0 4.14	(3.46–	4.95) 3.15	(2.62–	3.77)
III	(n	=	1389) 96.7 76.4 63.1 10.66	(8.82–	12.87) 7.75	(6.37–	9.42)
IV	(n	=	458) 65.7 24.6 17.3 51.44	(41.88–	63.19) 29.51 
(23.53–	36.99)
Unknown	(n	=	1386) 93.9 82.6 77.7 6.95	(5.59–	8.65) 4.76	(3.78–	5.99)
Differentiation
Low	(n	=	4127) 96.8 81.0 74.7 <0.001 1.00
Moderate	(n	=	5689) 99.1 93.5 87.5 0.40	(0.36–	0.45) 0.38	(0.34–	0.43)
High	(n	=	2865) 99.5 97.9 96.0 0.13	(0.11–	0.17) 0.14	(0.11–	0.17)
UK	(n	=	813) 84.4 64.1 55.2 2.08	(1.79–	2.41) 1.39	(1.16–	1.68)
Histology
Ductal	(n	=	10,454) 97.9 89.0 83.8 <0.001 1.00
Lobular	(n	=	1387) 98.8 91.6 85.2 0.85	(0.71–	1.01) 1.15	(0.96–	1.39)
Other	(n	=	1399) 97.9 94.8 93.6 0.47	(0.36–	0.60) 0.63	(0.49–	0.83)
Unknown	(n	=	254) 75.5 52.7 46.4 4.53	(3.62–	5.65) 1.77	(1.34–	2.33)
Diagnostic	period	(calendar	year)
2000–	2004	(n	=	4047) 97.2 87.8 82.5 <0.001 1.00
2005–	2009	(n	=	4410) 97.5 89.6 — 0.81	(0.72–	0.90) 0.82	(0.72–	0.92)
2010–	2014	(n	=	5034) 98.0 90.8 — 0.71	(0.60–	0.83) 0.72	(0.62–	0.85)
(Continues)
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benefits	 (Tesarova,	 2013).	 This	 did	 not	 apply	 to	 hormone	 therapy	
which,	as	previously	 reported,	was	more	common	 in	 the	70+	year	
age	range	(South	Australian	Cancer	Registry:	Epidemiology	Branch,	
2000).
Systemic therapy was least common in residents from the most 
disadvantaged areas and most common in the least disadvantaged 
areas,	 as	 shown	 previously	 (South	 Australian	 Cancer	 Registry:	
Epidemiology	 Branch,	 2000).	 Women	 born	 in	 other	 mainly	 non-	
English-	speaking	countries	were	also	more	likely	than	the	Australian-	
born to have systemic therapy. The reasons for these patterns are 
not clear and require further research. Similar patterns were not 
seen for hormone therapy which became more common over the 
study period.
Predictably,	 use	 of	 systemic	 therapies	 was	 greater	 for	 TNM	
stages that were more advanced than stage I and for less differen-
tiated	tumours	(Edge	&	Compton,	2010).	A	similar	pattern	was	not	
seen for hormone therapy which tended to be more common for 
more differentiated tumours.
Approximately	 60%	 of	 the	 cohort	 had	 radiotherapy	 in	 the	
12 months following diagnosis. The decreased use observed in older 
age	has	been	reported	previously	(South	Australian	Cancer	Registry:	
Epidemiology	Branch,	2000).	It	may	reflect	perceptions	of	reduced	
benefit in older women, although reduced mobility and poorer ac-
cess to radiotherapy in major metropolitan centres may have played 
a part. The reduced exposure seen in residents of outer regional and 
remote areas may reflect less ready access.
The	greater	use	of	radiotherapy	by	patients	born	in	mainly	non-	
English-	speaking	 countries	 may	 have	 been	 influenced	 by	 cultural	
factors, but also better access, as these patients tended more to 
reside in major city areas where radiotherapy centres were located 
(Australia	Bureau	of	Statistics,	2016,	2017).	Better	measures	of	eth-
nicity are needed to determine the role of this characteristic.
We	 were	 interested	 a	 priori	 in	 whether	 the	 non-	Australian-	
born were disadvantaged in accessing treatment services com-
pared	with	the	Australian-	born	due	to	language	or	cultural	barriers.	
The indication from this study that women born in another mainly 
English-	speaking	 country	 were	 less	 likely	 to	 be	 treated	 either	
by surgery, radiotherapy or systemic therapy was confirmatory. 
Statistically significant differences were not found for separate 






initial 12 months from diagnosis. While this could be artefactual due 
to	lack	of	access	to	treatment	data	outside	South	Australia,	or	be-












0	(n	=	12,535) 98.0 89.7 84.5 <0.001 1.00
1–	2	(n	=	907) 93.3 82.6 78.4 1.52	(1.27–	1.81) 1.12	(0.92–	1.35)
3+	(n	=	52) 61.1 48.7 36.5 6.04	(3.58–	10.12) 2.00	(1.06–	3.78)
Treatment
No	(n	=	210) 77.9 54.3 46.1 <0.001 1.00






TA B L E  5 Percentage	case	survival	from	breast	cancer	by	surgical	treatment:	female	breast	cancers	diagnosed	2000–	2014a.
Surgical treatment 1- year survival 5- year survival 10- year survival




No	(n	=	1290) 80.4 54.4 45.3 1.00 1.00
Conservative	(n	=	7498) 99.6 95.3 92.1 0.10	(0.08–	0.11) 0.31	(0.26–	0.36)
Mastectomy	(n	=	3491) 98.8 86.7 78.1 0.27	(0.24–	0.31) 0.49	(0.41–	0.57)
Both	surgery	(n	=	1215) 99.4 92.4 85.9 0.17	(0.14–	0.20) 0.42	(0.33–	0.52)
Abbreviations:	PBS,	Pharmaceutical	Benefits	Scheme;	SHR,	sub-	hazard	ratio.
aKaplan–	Meier	product-	limit	disease-	specific	estimates;	date	of	censoring	of	live	cases—	December	31,	2014.;	bDerived from unadjusted competing 
risk	analysis	using	death	of	other	causes	other	than	breast	cancer	as	competing	risk.;	cDerived	from	3	separate	competing	risk	regression	analyses	
with	each	using	death	of	other	causes	other	than	breast	cancer	as	competing	risk,	adjusting	for	age,	country	of	birth,	Indigenous	status,	residential	
socioeconomic disadvantage and remoteness, cancer stage, differentiation, histology, diagnosis time, and comorbidity status for systemic treatment, 
or	radiotherapy,	or	hormone	therapy	(data	source:	PBS	records).
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the	tumours	experienced	by	this	sub-	group	may	have	included	some	
with	 low	 potential	 to	 progress.	 Long-	term	 survivors	 are	 a	 group	
where further research could provide useful insights.







stage, histology and differentiation, as well as comorbidity status. 
Associations	of	treatment	with	survival	were	also	adjusted	for	these	
factors.	This	study	investigated	broader	population-	wide	treatment	
patterns, and associations with survival, than the earlier South 
Australian	report	(Roder	et	al.,	2017).
Limitations	should	be	noted.	Firstly,	radiotherapy	and	systemic	
therapy trends were susceptible to differences in recording over 
time, due to changes in funding mix and associated statistical col-
lection, such that use of trend data was limited to statistical adjust-
ment. In addition, treatment may be misclassified in the available 
administrative	 data.	 Secondly,	 disease-	specific	 survival	 was	 used,	
due to limited access to lifetables, although prior validation studies 
have shown this to be an accurate proxy for relative survival in South 
Australia	when	 subject	 to	 correction	by	 cancer	 registry	 staff	with	
access	 to	broader	clinical	 information	 (Roder	et	al.,	2017).	Thirdly,	
country of birth is far from ideal as a measure of ethnicity and fur-
ther development of a more appropriate measure is needed for pop-
ulation	studies.	Fourthly,	a	more	complete	measure	of	comorbidity	
is	needed,	ideally	incorporating	data	from	primary	care.	Lastly,	only	
limited data on hormonal therapies and targeted systemic therapies 





ses ideally would cover the entire screening and treatment pathway, 
including data on recurrence for determining recurrence rates and 
pre-	and-	post-	recurrence	treatment	and	survival.
In	 conclusion,	 the	 study	 illustrates	 the	 use	 of	 data	 linkage	 in	
Australia	to	describe	treatment	and	survival	at	a	population	level	for	
service evaluation. It indicates a high survival from breast cancer in 
South	Australia	by	international	standards.	Women	aged	70+	years	
had lower survival, and less treatment other than by hormone ther-
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